

圖 1-1-1 台南市城西里垃圾焚化爐空氣中戴奧辛毒性當量濃度 (fg I-TEQ/Nm^3)的擴散模擬圖

備註：面積由民國 92 年航照圖估算或公告地號面積計算。

圖1-1-2場址已公告污染範圍分區示意圖



圖3-1-1 本計畫研究架構



a：台南市政府衛生局所提供

圖3-4-1 採樣對象通知流程圖



圖3-4-2 本研究計畫血液前處理流程圖



圖 3-4-2 本研究計畫血液前處理流程圖(續)



圖3-4-3 總汞分析儀元件配置圖



圖3-4-4 總汞分析儀操作流程



圖3-6-1 本研究計畫採樣作業圖表流程



圖3-6-2 樣本檢驗品保流程圖



圖3-6-3 本計畫空白樣本原始上機濃度17種戴奧辛/呋喃同源物管制結果



圖3-6-4 本計畫17種戴奧辛/呋喃同源物偵測極限總毒性當量濃度管制結果



圖3-6-5 本計畫混合血清17種戴奧辛/呋喃同源物總毒性當量濃度管制結果



圖3-6-6 本計畫樣本分析17種戴奧辛/呋喃同源物同位素標記標準品回收率管制結果



圖3-6-7 本計畫十七種多氯戴奧辛/呋喃同源物監測時窗區查核執行結果之一



圖3-6-8 本計畫十七種多氯戴奧辛/呋喃同源物儀器靈敏度確認結果之一



圖3-6-9 本計畫十七種多氯戴奧辛/呋喃同源物層析解析度執行結果之一



圖3-6-10 本計畫十七種多氯戴奧辛/呋喃同源物層析解析度執行結果之一

Sample Name: A8B14-1S001 Sample ID: CS03
Acq.Date 14-Nov-09
Method: D:\MASSLYNX\PROJECT\ M1613\A8B14-1.PRO\MethDB\NIEA M1613A8B14-1MDB
Sample List: D:\MASSLYNX\ PROJECT\M1613\A8B14-1PRO\SampleDB\A8B14-1CAL

	Type	Name	Amount	Area	RA	Ratio Flag	RT	RRF	MODIFIED	RRF Mean	%RSD	S/N	Sec. S/N
1	Unk	2,3,7,8-TCDF	0.05	1302.234	0.70	YES	35.13	0.86	bb	0.921	8.37	46.991	49.465
2	Unk	1,2,3,7,8-PeCDF	0.25	6134.152	1.70	YES	41.95	0.79	bb	0.867	9.80	436.577	246.301
3	Unk	2,3,4,7,8-PeCDF	0.25	6172.515	1.60	YES	42.84	0.81	bb	0.913	10.72	472.665	287.583
4	Unk	1,2,3,4,7,8-HxCDF	0.25	6103.379	1.30	YES	45.19	0.96	bd	1.055	9.91	285.783	539.584
5	Unk	1,2,3,6,7,8-HxCDF	0.25	6559.413	1.20	YES	45.30	0.89	db	0.984	10.77	298.08	549.145
6	Unk	2,3,4,6,7,8-HxCDF	0.25	6014.483	1.20	YES	45.78	0.88	bd	0.957	9.99	258.72	525.937
7	Unk	1,2,3,7,8,9-HxCDF	0.25	5180.39	1.30	YES	46.51	0.86	bb	0.964	11.27	212.785	392.448
8	Unk	1,2,3,4,6,7,8-HpCDF	0.25	5894.411	1.00	YES	47.88	1.15	bd	1.254	10.31	329.397	360.79
9	Unk	1,2,3,4,7,8,9-HpCDF	0.25	4039.643	1.10	YES	49.48	1.00	dd	1.069	9.88	182.86	209.936
10	Unk	OCDF	0.5	3945.891	0.90	YES	52.57	0.81	bb	0.886	14.63	225.543	209.986
11	Unk	2,3,7,8-TCDD	0.05	760.576	0.70	YES	36.62	0.81	bb	0.817	4.86	40.8	53.314
12	Unk	1,2,3,7,8-PeCDD	0.25	3320.072	1.60	YES	43.11	0.74	bb	0.822	9.55	231.346	126.183
13	Unk	1,2,3,4,7,8-HxCDD	0.25	3320.871	1.30	YES	45.90	0.72	dd	0.757	9.18	215.97	109.534
14	Unk	1,2,3,6,7,8-HxCDD	0.25	3308.31	1.30	YES	45.98	0.66	db	0.739	10.53	202.1	114.892
15	Unk	1,2,3,7,8,9-HxCDD	0.25	3621.491	1.30	YES	46.21	0.75	bb	0.796	11.12	215.982	107.939
16	Unk	1,2,3,4,6,7,8-HpCDD	0.25	3631.742	1.10	YES	48.93	0.94	bb	0.990	6.46	210.257	276.731
17	Unk	OCDD	0.5	4164.767	0.90	YES	52.33	0.85	bb	0.903	7.19	292.689	206.603
18	IS/RT	13C-2,3,7,8-TCDF	50	1523239.938	0.80	YES	35.12	1.45	bb	1.445	1.46	5568.158	6746.606
19	IS	13C-1,2,3,7,8-PeCDF	50	1556220.75	1.60	YES	41.92	1.48	bb	1.477	3.72	9959.517	7589.29
20	IS	13C-2,3,4,7,8-PeCDF	50	1517996.563	1.60	YES	42.83	1.45	bb	1.407	2.98	11334.85	8631.531
21	IS	13C-1,2,3,4,7,8-HxCDF	50	1276648.719	0.50	YES	45.19	1.22	bd	1.258	2.15	3927.852	4670.257
22	IS	13C-1,2,3,6,7,8-HxCDF	50	1475702.282	0.50	YES	45.28	1.41	dd	1.468	2.78	4570.194	5298.468
23	IS	13C-2,3,4,6,7,8-HxCDF	50	1368836.969	0.50	YES	45.75	1.31	bb	1.346	2.45	4071.596	4867.112
24	IS	13C-1,2,3,7,8,9-HxCDF	50	1201862.969	0.50	YES	46.48	1.15	bb	1.148	3.17	3307.025	3873.638
25	IS	13C-1,2,3,4,6,7,8-HpCDF	50	1028052.906	0.50	YES	47.86	0.98	bb	0.972	0.79	5723.743	9565.952
26	IS	13C-1,2,3,4,7,8,9-HpCDF	50	806658.094	0.50	YES	49.48	0.77	bb	0.730	3.16	3665.525	6158.724
27	IS	13C-2,3,7,8-TCDD	50	934612.407	0.80	YES	36.58	0.89	bb	0.866	3.02	4247.315	6486.525
28	IS	13C-1,2,3,7,8-PeCDD	50	892194.907	1.60	YES	43.10	0.85	bb	0.843	3.18	14968.06	9196.352
29	IS	13C-1,2,3,4,7,8-HxCDD	50	919495.907	1.30	YES	45.89	0.88	bd	0.896	1.87	6736.79	6384.154
30	IS	13C-1,2,3,6,7,8-HxCDD	50	1006553.751	1.20	YES	45.97	0.96	db	0.998	2.17	6870.821	6863.153
31	IS	13C-1,2,3,4,6,7,8-HpCDD	50	771201.75	1.00	YES	48.91	0.74	bb	0.677	5.27	3735.391	3495.082
32	IS	13C-OCDD	100	975661.187	0.90	YES	52.32	0.47	bb	0.439	3.64	24353.64	16186.5
33	RS	13C-1,2,3,4-TCDD	50	1049598.719	0.80	YES	35.48	20991.97	bb	21588.330	13.84	5238.104	7613.033
34	RS/RT	13C-1,2,3,7,8,9-HxCDD	50	1047395.938	1.20	YES	46.20	20947.92	bb	19822.053	16.03	6858.636	6777.903
35	C/UP	37Cl-2,3,7,8-TCDD	0.05	799.124	0.00		36.62	0.76	bb	0.757	5.08	52.853	

圖3-6-11 本計畫十七種多氯戴奧辛/呋喃同源物平均相對感應因子建立RRF相對平均標準差(RSD%)結果之一

Sample Name: A8B24-2S001 Sample ID: VER
Acq.Date 24-Nov-09
Method: D:\MASSLYNX\PROJECT\ M1613\A8B14-1PRO\MethDB\NIEA M1613A8B14-1MDB
Sample List: D:\MASSLYNX\ PROJECT\M1613\A8B14-1.PRO\SampleDB\A8B24-2.RSL
Cal D:\MASSLYNX\ PROJECT\M1613\A8B14-1PRO\SampleDB\A8B14-1CAL

	Type	Name	Area	RA	Ratio Flag	RT	RRF	RRF Mean	Different%	Range	Mod	S/N	Sec. S/N	native-lable rt
1	Unk	2,3,7,8-TCDF	5930.00	0.76	YES	35.09	0.799	0.921	-13%	20%	bd	137.20	327.05	-0.03
2	Unk	1,2,3,7,8-PeCDF	28772.58	1.61	YES	41.94	0.806	0.867	-7%	20%	bb	1916.21	1552.23	-0.02
3	Unk	2,3,4,7,8-PeCDF	29201.06	1.51	YES	42.84	0.837	0.913	-8%	20%	bb	2053.44	1787.04	-0.03
4	Unk	1,2,3,4,7,8-HxCDF	28855.69	1.29	YES	45.19	1.052	1.055	0%	20%	bd	1607.44	1641.24	-0.02
5	Unk	1,2,3,6,7,8-HxCDF	32657.54	1.29	YES	45.30	1.003	0.984	2%	20%	db	1791.15	1836.63	-0.02
6	Unk	2,3,4,6,7,8-HxCDF	28932.30	1.26	YES	45.78	0.971	0.957	1%	20%	bb	1578.43	1563.06	-0.01
7	Unk	1,2,3,7,8,9-HxCDF	23466.57	1.27	YES	46.51	0.980	0.964	2%	20%	bb	1143.53	1175.83	-0.01
8	Unk	1,2,3,4,6,7,8-HpCDF	24470.27	1.01	YES	47.89	1.208	1.254	-4%	20%	bb	2500.02	1306.97	-0.01
9	Unk	1,2,3,4,7,8,9-HpCDF	15751.87	1.03	YES	49.51	1.023	1.069	-4%	20%	bd	1359.32	704.73	-0.02
10	Unk	OCDF	15253.99	0.90	YES	52.64	0.923	0.886	4%	20%	bb	994.74	1025.93	
11	Unk	2,3,7,8-TCDD	3923.87	0.81	YES	36.56	0.763	0.817	-7%	20%	bd	146.90	329.96	-0.04
12	Unk	1,2,3,7,8-PeCDD	17153.70	1.65	YES	43.09	0.826	0.822	0%	20%	bb	1466.50	1167.14	-0.01
13	Unk	1,2,3,4,7,8-HxCDD	14087.79	1.32	YES	45.90	0.798	0.757	5%	20%	bd	1406.33	548.95	-0.01
14	Unk	1,2,3,6,7,8-HxCDD	15783.43	1.30	YES	45.98	0.764	0.739	3%	20%	db	1460.29	582.12	-0.01
15	Unk	1,2,3,7,8,9-HxCDD	15781.76	1.29	YES	46.23	0.824	0.796	4%	20%	bb	1415.15	563.72	0.00
16	Unk	1,2,3,4,6,7,8-HpCDD	13382.71	1.03	YES	48.95	0.967	0.990	-2%	20%	bb	1188.56	834.27	-0.01
17	Unk	OCDD	14480.59	0.95	YES	52.40	0.876	0.903	-3%	20%	bd	1309.08	1136.53	0.00
18	IS/RT	13C-2,3,7,8-TCDF	1484793.13	0.76	YES	35.06	1.386	1.445	-4%	25%	bb	5491.10	5885.02	
19	IS	13C-1,2,3,7,8-PeCDF	1428163.25	1.58	YES	41.92	1.333	1.477	-10%	25%	bb	4158.66	5343.91	
20	IS	13C-2,3,4,7,8-PeCDF	1395884.81	1.56	YES	42.81	1.303	1.407	-7%	25%	bb	4685.41	6099.04	
21	IS	13C-1,2,3,4,7,8-HxCDF	1096744.69	0.53	YES	45.17	1.394	1.258	11%	25%	bd	3578.79	7893.72	
22	IS	13C-1,2,3,6,7,8-HxCDF	1302370.56	0.54	YES	45.28	1.656	1.468	13%	25%	dd	4361.05	9181.91	
23	IS	13C-2,3,4,6,7,8-HxCDF	1191753.25	0.53	YES	45.77	1.515	1.346	13%	25%	bb	4012.62	8404.18	
24	IS	13C-1,2,3,7,8,9-HxCDF	957741.03	0.54	YES	46.50	1.218	1.148	6%	25%	bb	2855.54	6119.74	
25	IS	13C-1,2,3,4,6,7,8-HpCDF	810294.47	0.45	YES	47.88	1.030	0.972	6%	25%	bb	4299.37	6927.90	
26	IS	13C-1,2,3,4,7,8,9-HpCDF	616096.56	0.43	YES	49.49	0.783	0.730	7%	25%	bb	2658.93	4601.28	
27	IS	13C-2,3,7,8-TCDD	1028256.69	0.80	YES	36.52	0.960	0.866	11%	25%	bb	5184.87	5174.98	
28	IS	13C-1,2,3,7,8-PeCDD	831128.81	1.59	YES	43.08	0.776	0.843	-8%	25%	bb	9492.21	13345.91	
29	IS	13C-1,2,3,4,7,8-HxCDD	705924.00	1.31	YES	45.89	0.897	0.896	0%	25%	bd	5044.07	4656.71	
30	IS	13C-1,2,3,6,7,8-HxCDD	826071.84	1.26	YES	45.97	1.050	0.998	5%	25%	db	5418.17	5659.25	
31	IS	13C-1,2,3,4,6,7,8-HpCDD	553720.16	1.05	YES	48.94	0.704	0.677	4%	25%	bb	3511.74	3559.04	
32	IS	13C-OCDD	660978.00	0.87	YES	52.40	0.420	0.439	-4%	25%	bb	21172.80	16777.35	
33	RS	13C-1,2,3,4-TCDD13C-1,:	1071224.13	0.80	YES	35.42	21424.483	21588.330			bb	5873.17	5949.58	
34	RS/RT	13C-1,2,3,7,8,9-HxCDD	786554.53	1.22	YES	46.21	15731.091	19822.053			bb	5091.94	5096.24	
35	C/UP	37Cl-2,3,7,8-TCDD	4223.02			36.56	0.788	0.757	4%	25%	bb	377.94		

圖3-6-12 本計畫十七種多氯戴奧辛/呋喃同源物平均相對感應因子查核結果之一


比較三里居民疾病盛行率後
選取欲調查之疾病
（疾病ICD-9或A-code編碼如附件一）
研究對象:簽署同意健保資料連結同意書之三里居民
研究對象先依血液戴奧辛及總汞濃度分成20 組
(分組後各組ID如附件二)
各分組ID後附掛基本資料包括:
基本資料：年齡(18歲以上，5歲一組)
及性別(男女)
生活習慣：吸煙
危險因子：血糖>126 mg/dL、
血壓(140/90 mmHg)、
血脂肪(HDL:35, TG:250 mg/dL)、
肥胖（BMI ≥ 30）
1996-2009年
健保資料庫
✱門診處方及治療明細資料檔
醫事機構地區代號、出生日期、身份證號、性別、國際疾病分類號一～三等變項。
✱住院醫療費用清單資料檔
醫事機構地區代號、身份證號、出生日期、性別、主診斷代碼、次診斷代碼一～四等變項。
透過分層條件串檔
三里居民第一次
門診及住院資料
1.分析中石化三里居民一般疾病就醫率與戴奧辛及總汞暴露之相關

圖4-3-1 研究架構圖